BCMA-CD38 bispecific CAR-T cell therapy
/ Shengyan Pharmaceutical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 07, 2019
CAR T-cell therapy targeting BCMA and CD38 induces positive responses in multiple myeloma
(Targeted Oncology)
- P1, N=22; "'This is the first clinical trial of anti-BCMA and CD38 dual-targeted CAR T-cell therapy in refractory multiple myeloma. Our study demonstrates improved efficacy and manageable safety,'....Investigators plan to continue follow up on these patients for 2 years. A phase II trial is being planned in both China and the United States to test the treatment’s efficacy in a larger number of patients."
New P2 trial • P1 data
1 to 1
Of
1
Go to page
1